Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL)
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Martha Q. Lacy, Kah-Whye Peng, Stephen J. Russell, Amylou C. Dueck, Mrinal M. Patnaik, Thomas E. Witzig, Brenda F Ginos, Francis K. Buadi, Angela Dispenzieri, Morie A. Gertz, Ronald S. Go, Suzanne R. Hayman, John A. Lust, David Dingli, S. Vincent Rajkumar, Nelson Leung, Rahma Warsame, Wilson I Gonsalves, Taxiarchis Kourelis, Eli Muchtar, Stephen Broski, Robert C Murphy, Prashant Kapoor, Robert A. Kyle, Steven Zeldenrust, Aref Al-Kali, Mark R. Litzow, Shruthi Naik, Mark J Federspiel, Shaji K. Kumar
Institutions: Mayo Clinic, Mayo Clinic in Arizona
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4205897838